Your session is about to expire
← Back to Search
Bicalutamide + BCG for Bladder Cancer (BicaBCa Trial)
BicaBCa Trial Summary
This trial is comparing two treatments for bladder cancer. The first is the standard induction BCG, and the second is bicalutamide and standard induction BCG.
BicaBCa Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBicaBCa Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 116 Patients • NCT02085252BicaBCa Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a man aged 18 or older.My liver tests are more than twice the normal limit.My urologist has recommended BCG treatment for me.I have not had a heart attack or been hospitalized for heart failure in the last year.I received gemcitabine, epirubicin, or mitomycin C right after surgery.My bladder cancer has not spread into the muscle layer.I am taking or will take coumadin.My kidney function is low, with an eGFR below 30.I had prostate cancer treated over 5 years ago with no signs of it coming back.Your blood test shows a low level of a type of white blood cell called neutrophils.I have low testosterone or am on hormone therapy for prostate cancer or other conditions.I have received BCG therapy within the last 5 years.I've had bladder treatment with chemo directly into the bladder in the last 5 years.I have had a blood clot in my veins within the last 3 years.My blood pressure is controlled and not above 160 despite treatment.
- Group 1: Control Arm
- Group 2: Bicalutamide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are contributing to this research endeavor?
"Indeed, the clinical trial is currently accepting candidates. Clinicaltrials.gov records reveal that it was first posted on June 23rd 2022 and subsequently updated on July 13th of the same year. The team needs to enroll 160 individuals from 1 medical site."
Does this clinical trial presently have the capacity to accept participants?
"According to clinicaltrials.gov, this medical experiment is currently accepting applicants. It was first listed on June 23rd 2022 and the last recorded update occurred on July 13th 2022."
Has Bicalutamide been greenlit by the Food and Drug Administration?
"Due to the lack of evidence on Bicalutamide's efficacy, our team rated its safety as a 2. This is because it has only been tested for safety in Phase 2 trials."
Share this study with friends
Copy Link
Messenger